Treating amiodarone-induced thyrotoxicosis with radioactive iodine.
Amiodarone use in the United States is increasing including a role in advanced cardiac life support protocols. There has been a significant increase in hypothyroidism, destructive thyroiditis (type II), and iodine-induced thyrotoxicosis (type I) with amiodarone. Preexisting thyroid disease and status of iodine intake can determine the nature of iodine-induced thyroid disease. Treating amiodarone-induced thyrotoxicosis (AIT) may include traditional antithyroid agents, glucocorticoids, and surgery. Usually, it is assumed the radioactive iodine uptake (RAIU) will be low, and this choice as a treatment modality is excluded at the initial visit. We report a satisfactory outcome in a patient with AIT using radioactive iodine. The role of radioactive iodine in treating AIT is reviewed
Iskandar
Said B
SB
Department of Internal Medicine, East Tennessee State University, Johnson City, USA.
Jordan
Richard M
RM
Richard
M Jordan
MJ
Peiris
Alan N
AN
D000368:Aged; D000638:Amiodarone / Q000009:adverse effects* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D018570:Risk Assessment; D012720:Severity of Illness Index; D013960:Thyroid Function Tests; D013971:Thyrotoxicosis / Q000139:chemically induced* / Q000532:radiotherapy*; D016896:Treatment Outcome
D007457:Iodine Radioisotopes; D000638:Amiodarone